These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 31909868)

  • 1. Treatment-to-Target With Apremilast in Psoriatic Arthritis: The Probability of Achieving Targets and Comprehensive Control of Disease Manifestations.
    Mease PJ; Gladman DD; Ogdie A; Coates LC; Behrens F; Kavanaugh A; McInnes I; Queiro R; Guerette B; Brunori M; Teng L; Smolen JS
    Arthritis Care Res (Hoboken); 2020 Jun; 72(6):814-821. PubMed ID: 31909868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Baseline Disease Activity Predicts Achievement of cDAPSA Treatment Targets With Apremilast: Phase III Results in DMARD-naïve Patients With Psoriatic Arthritis.
    Mease PJ; Kavanaugh A; Ogdie A; Wells AF; Bergman M; Gladman DD; Richter S; Teng L; Jardon S; Smolen JS
    J Rheumatol; 2022 Jul; 49(7):694-699. PubMed ID: 35428720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Different Remission and Low Disease Definitions in Psoriatic Arthritis and Evaluation of Their Prognostic Value.
    Coates LC; Gottlieb AB; Merola JF; Boone C; Szumski A; Chhabra A
    J Rheumatol; 2019 Feb; 46(2):160-165. PubMed ID: 30323006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Composite Indices Tailored for Psoriatic Arthritis Treated with csDMARD and bDMARD: A Cross-sectional Analysis of a Longitudinal Cohort.
    Lubrano E; De Socio A; Perrotta FM
    J Rheumatol; 2017 Aug; 44(8):1159-1164. PubMed ID: 28572467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of IL-12/23 inhibition (ustekinumab) versus tumour necrosis factor inhibition in psoriatic arthritis: observational PsABio study results.
    Smolen JS; Siebert S; Korotaeva TV; Selmi C; Bergmans P; Gremese E; Joven-Ibáñez B; Katsifis G; Noël W; Nurmohamed MT; Richette P; Sfikakis PP; de Vlam K; Theander E; Gossec L
    Ann Rheum Dis; 2021 Nov; 80(11):1419-1428. PubMed ID: 34162594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3).
    Edwards CJ; Blanco FJ; Crowley J; Birbara CA; Jaworski J; Aelion J; Stevens RM; Vessey A; Zhan X; Bird P
    Ann Rheum Dis; 2016 Jun; 75(6):1065-73. PubMed ID: 26792812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Phase III, Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis: Results of the PALACE 2 Trial.
    Cutolo M; Myerson GE; Fleischmann RM; Lioté F; Díaz-González F; Van den Bosch F; Marzo-Ortega H; Feist E; Shah K; Hu C; Stevens RM; Poder A
    J Rheumatol; 2016 Sep; 43(9):1724-34. PubMed ID: 27422893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Longterm (52-week) results of a phase III randomized, controlled trial of apremilast in patients with psoriatic arthritis.
    Kavanaugh A; Mease PJ; Gomez-Reino JJ; Adebajo AO; Wollenhaupt J; Gladman DD; Hochfeld M; Teng LL; Schett G; Lespessailles E; Hall S
    J Rheumatol; 2015 Mar; 42(3):479-88. PubMed ID: 25593233
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ideal target for psoriatic arthritis? Comparison of remission and low disease activity states in a real-life cohort.
    van Mens LJJ; van de Sande MGH; van Kuijk AWR; Baeten D; Coates LC
    Ann Rheum Dis; 2018 Feb; 77(2):251-257. PubMed ID: 29080861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early and sustained efficacy with apremilast monotherapy in biological-naïve patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE).
    Nash P; Ohson K; Walsh J; Delev N; Nguyen D; Teng L; Gómez-Reino JJ; Aelion JA;
    Ann Rheum Dis; 2018 May; 77(5):690-698. PubMed ID: 29343507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1-3 pooled analysis.
    Kavanaugh A; Gladman DD; Edwards CJ; Schett G; Guerette B; Delev N; Teng L; Paris M; Mease PJ
    Arthritis Res Ther; 2019 May; 21(1):118. PubMed ID: 31077258
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum sCD40L levels are increased in patients with psoriatic arthritis and are associated with clinical response to apremilast.
    Venerito V; Natuzzi D; Bizzoca R; Lacarpia N; Cacciapaglia F; Lopalco G; Iannone F
    Clin Exp Immunol; 2020 Aug; 201(2):200-204. PubMed ID: 32383167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient-reported Health-related Quality of Life with apremilast for psoriatic arthritis: a phase II, randomized, controlled study.
    Strand V; Schett G; Hu C; Stevens RM
    J Rheumatol; 2013 Jul; 40(7):1158-65. PubMed ID: 23588944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apremilast for biologic-naïve, peripheral psoriatic arthritis, including patients with early disease: results from the APROACH observational prospective study.
    Sfikakis PP; Vassilopoulos D; Katsifis G; Vosvotekas G; Dimitroulas T; Sidiropoulos P; Vounotrypidis P; Bogdanos DP; Georgountzos AΙ; Bounas AG; Georgiou P; Gazi S; Kataxaki E; Liossis SN; Theodorou E; Papagoras C; Theotikos E; Vlachoyiannopoulos P; Voulgari PV; Kekki A; Antonakopoulos N; Boumpas DT
    Rheumatol Int; 2023 May; 43(5):889-902. PubMed ID: 36856816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retrospective evaluation of patient profiling and effectiveness of apremilast in an Italian multicentric cohort of psoriatic arthritis patients.
    Favalli EG; Conti F; Selmi C; Iannone F; Bucci R; D'Onofrio F; Carlino G; Santo L; Semeraro A; Zuccaro C; D'Angelo S; Atzeni F; Marino F; Monti S; Guidelli GM; Spinelli FR; Biggioggero M; Caporali R
    Clin Exp Rheumatol; 2020; 38(1):19-26. PubMed ID: 31074721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and effectiveness of apremilast in Japanese patients with psoriatic disease: Results of a post-marketing surveillance study.
    Ohtsuki M; Okubo Y; Saeki H; Igarashi A; Imafuku S; Abe M; Chaudhari S; Yaguchi M; Emoto A; Morita A
    J Dermatol; 2024 Jul; 51(7):950-963. PubMed ID: 38775204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study.
    Schett G; Wollenhaupt J; Papp K; Joos R; Rodrigues JF; Vessey AR; Hu C; Stevens R; de Vlam KL
    Arthritis Rheum; 2012 Oct; 64(10):3156-67. PubMed ID: 22806399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Musculoskeletal ultrasound in monitoring response to apremilast in psoriatic arthritis patients: results from a longitudinal study.
    Ceccarelli F; Lucchetti R; Perricone C; Spinelli FR; Cipriano E; Truglia S; Miranda F; Riccieri V; Di Franco M; Scrivo R; Alessandri C; Valesini G; Conti F
    Clin Rheumatol; 2019 Nov; 38(11):3145-3151. PubMed ID: 31317423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apremilast: A Review in Psoriasis and Psoriatic Arthritis.
    Keating GM
    Drugs; 2017 Mar; 77(4):459-472. PubMed ID: 28213862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methotrexate achieves major cDAPSA response, and improvement in dactylitis and functional status in psoriatic arthritis.
    Appani SK; Devarasetti PK; Irlapati RVP; Rajasekhar L
    Rheumatology (Oxford); 2019 May; 58(5):869-873. PubMed ID: 30590763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.